Učitavanje...
Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients
BACKGROUND: Cetuximab and bevacizumab reportedly improve the survival of patients with metastatic colorectal cancer (mCRC), but their most effective sequence of administration is unknown. The aim of this study was to compare the survival of patients with mCRC treated with cetuximab after bevacizumab...
Spremljeno u:
| Izdano u: | Onco Targets Ther |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4648607/ https://ncbi.nlm.nih.gov/pubmed/26648737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S89241 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|